Pain Therapeutics Inc (PTIE.O)
5.29USD
9 Dec 2009
$0.14 (+2.72%)
$5.15
$5.11
$5.31
$5.01
140,870
258,469
$8.15
$3.20
PTIE.O
About
Overall
| Beta: | 0.50 |
| Market Cap (Mil.): | $223.17 |
| Shares Outstanding (Mil.): | 42.19 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| PTIE.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.56 | 4.57 |
| EPS (TTM): | -126.44 | -- | -- |
| ROI: | -2.69 | 1.79 | 2.77 |
| ROE: | -4.37 | 2.41 | 4.04 |
UPDATE 2-King wins OK for morphine meant to thwart abuse
* Shares rise 2 percent in after-market trade (Adds analyst, FDA comments, updates shares)
HEADLINE STOCKS-Some U.S. stocks on the move on July 7
(Updates to afternoon trading, adds Trinity, Blackstone and Steel Dynamics)
HEADLINE STOCKS-Some U.S. stocks on the move on July 7
(Updates to after the open, adds ConocoPhillips, Southwest Airlines, Fluor and Weyerhaeuser. Updates Boeing.)
UPDATE 2-King, Pain Therapeutics may refile Remoxy in 2010
* King shares fall 0.5 pct; Pain Thera drops 6.9 pct (Adds background, analyst comment, shares)
HEADLINE STOCKS-Some U.S. stocks to watch on July 7
NEW YORK, July 7 (Reuters) - Some U.S. stocks to watch on Tuesday:
UPDATE 2-US: new opioids could come as risk plans developed
WASHINGTON, May 28 (Reuters) - New opioid painkiller drugs could be approved before U.S. regulators impose stronger safety measures on a broad group of the medicines, a U.S. health official said on Thursday.
US RESEARCH SUMMARY-Non-S&P 500 April 17 1407 GMT
Following is a summary of research actions on non-S&P 500 companies reported
UPDATE 3-US opioid makers need plan to safeguard users-FDA
(Adds details on use, deaths, company and analyst comments)
FDA declines to approve King, Pain Therapeutics' Remoxy
BANGALORE (Reuters) - U.S. health regulators declined to approve King Pharmaceuticals Inc's and Pain Therapeutics Inc's abuse-resistant painkiller Remoxy in its current form, sending Pain Therapeutics 's shares down as much as 29 percent to a new year-low.
FDA declines to approve King, Pain Therapeutics' Remoxy
BANGALORE (Reuters) - U.S. health regulators declined to approve King Pharmaceuticals Inc's and Pain Therapeutics Inc's abuse-resistant painkiller Remoxy in its current form, sending Pain Therapeutics 's shares down as much as 29 percent to a new year-low.
Competitors
| Price | Change | |
|---|---|---|
| Abbott Laboratories (ABT.N) | $53.61 | +0.37 |
| Cephalon, Inc. (CEPH.OQ) | $57.15 | +0.42 |
| Endo Pharmaceuticals (ENDP.OQ) | $19.51 | -0.16 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | ₪20,080.00 | +90.00 |
| Watson Pharmaceuticals, Inc. (WPI.N) | $37.65 | -0.12 |
| Forest Laboratories, Inc. (FRX.N) | $31.14 | +0.18 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
